265 related articles for article (PubMed ID: 16029627)
1. [Comparison of therapeutic effects of low-dose versus high-dose interferon alpha-2b treatment on chronic myelocytic leukemia: a prospective randomized study].
Du JW; Zhu P; Tian D; Dong ZR; Yang SL; Li SB; Tang YH; Liu H; Cen XN; Zhang Y; Zhu Q; Zhu YL; Yang Y; Wang DX; Wang Z; Cui H; Ma YG; Chen WM; Liu FQ; Ma J; Wang JW; Shen T; Da WM
Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1305-9. PubMed ID: 16029627
[TBL] [Abstract][Full Text] [Related]
2. BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients.
Pane F; Mostarda I; Selleri C; Salzano R; Raiola AM; Luciano L; Saglio G; Rotoli B; Salvatore F
Blood; 1999 Oct; 94(7):2200-7. PubMed ID: 10498589
[TBL] [Abstract][Full Text] [Related]
3. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
[TBL] [Abstract][Full Text] [Related]
4. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
Song YQ; Li W; Kong LH; Wang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
[TBL] [Abstract][Full Text] [Related]
5. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
6. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Müller MC; Gattermann N; Lahaye T; Deininger MW; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld DK; Schneller F; Krause SW; Nerl C; Sayer HG; Ottmann OG; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Dec; 17(12):2392-400. PubMed ID: 14523462
[TBL] [Abstract][Full Text] [Related]
8. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
[TBL] [Abstract][Full Text] [Related]
9. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
10. [Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients].
Tang LJ; Chen HC; Peng XH
Hunan Yi Ke Da Xue Xue Bao; 2000 Dec; 25(6):570-2. PubMed ID: 12516408
[TBL] [Abstract][Full Text] [Related]
11. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
12. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to alpha-interferon in chronic myelogenous leukemia.
Inoue T; Tojo A; Tsuchimoto D; Okamoto S; Ogura H; Tani K; Ozawa K; Shibuya M; Asano S
Leukemia; 1992 Sep; 6(9):948-51. PubMed ID: 1518306
[TBL] [Abstract][Full Text] [Related]
13. [Detection of bcr/abl fusion gene changes in patients with chronic myeloid leukemia after allo-HSCT by real-time quantitative reverse transcription polymerase chain reaction and its significance].
Xue M; Wang HX; Duan LN; Yan HM; Zhu L; Liu J; Ding L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1350-3. PubMed ID: 19099642
[TBL] [Abstract][Full Text] [Related]
14. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
Schulze E; Krahl R; Thalmeier K; Helbig W
Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
[TBL] [Abstract][Full Text] [Related]
15. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
16. Real-time quantification for BCR-ABL transcripts in chronic myeloid leukaemia patients in UKMMC, Malaysia.
Wong FL; Hamidah NH; Hawa AA; Nurul AN; Leong CF; Saw F; Ainoon O
Malays J Pathol; 2011 Dec; 33(2):107-12. PubMed ID: 22299211
[TBL] [Abstract][Full Text] [Related]
17. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
[TBL] [Abstract][Full Text] [Related]
19. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
Hochhaus A; Reiter A; Saussele S; Reichert A; Emig M; Kaeda J; Schultheis B; Berger U; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
Blood; 2000 Jan; 95(1):62-6. PubMed ID: 10607685
[TBL] [Abstract][Full Text] [Related]
20. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
Ross DM; Branford S; Moore S; Hughes TP
Leukemia; 2006 Apr; 20(4):664-70. PubMed ID: 16482210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]